ClinicalTrials.gg
Active, not recruitingNCT05460273Updated Aug 31, 2026Results posted

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

A Phase 1/2 interventional study of Datopotamab Deruxtecan (Dato-DXd) in Carcinoma, Non-Small-Cell Lung and Triple Negative Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 21 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
119
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 19 under way, 9 of them phase 3. datopotamab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
17th of 21
119 · median 278
Started
2022
with 3 others
Phase 1/2
2 of 21
1 open now
Primary completion
2023-11
later than 0 of 18 live
Registered
10th of 21
by date
Lead sponsor
11 of 21
AstraZeneca

Among the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 4 that started in 2022, is one of 2 in phase 1/2, reaches primary completion later than 0 of the 18 other live ones, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat advanced Triple-Negative Breast Cancer (TNBC) and Non-Small-Cell Lung Cancer (NSCLC). "Advanced" usually means that the cancer keeps growing even with treatment. The cancer may also be "metastatic", which means that it has spread to other parts of the body or the surrounding tissue.

The study drug, Datopotamab deruxtecan, is designed to work by attaching to the tumor cells and stopping the tumor growth. Datopotamab deruxtecan is also known as Dato-DXd.

In this study, the researchers want to find out how well Dato-DXd works to stop tumors from growing in Chinese participants with NCSLC or TNBC. This is the first time Dato-DXd is being studied in Chinese population.

Participants in this study will get Dato-DXd through a needle as an injection. They will get 1 dose of Dato-DXd every 3 weeks until their cancer gets worse or they leave the study for another reason.

Participants will visit their study sites at least once every 3 weeks for as long as they are in the study. The study doctors will take blood samples every 3 weeks and take images of the participants' tumors every 6 weeks until the participant leaves the study.

Read the detailed description

This is a Phase 1/Phase 2, multicentre, open-label, multiple-cohort study, which is designed to evaluate the efficacy, safety, Pharmacokinetic, and immunogenicity of Dato-DXd in adult Chinese participants with advanced or metastatic solid tumours. It is a single-arm study with no blinding.

This study is divided into different cohorts. Participants of the same cohort are with the same tumour type. The starting cohorts are Cohort 1 (NSCLC) and Cohort 2 (TNBC). Future cohorts will consist of other advanced or metastatic solid tumour types, including, but not limited to, advanced/unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma or urothelial carcinoma that is refractory or intolerant to SoC therapy or for which no Standard of Care therapy is available.

Cohort 1 and Cohort 2 will be prioritised for immediate enrolment and the protocol will be amended as needed for the future cohorts.

Cohort 1: The target population of Cohort 1 is adult Chinese participants with advanced or metastatic NSCLC with or without actionable genomic alterations(AGAs) (ie, alterations in genes with approved therapies, such as EGFR, ALK, or other known AGAs).

Eligible participants without AGAs will have been previously treated with platinum-based chemotherapy and anti-PD-1/anti-PD-L1 monoclonal antibody either in combination or sequentially. Participants without AGAs who received anti-PD-1/anti-PD-L1 monoclonal antibody as frontline therapy may have received the combination of platinum-based chemotherapy and anti-PD-1/anti-PD-L1 monoclonal antibody in the second-line setting.

Eligible participants with AGAs will have been previously treated with one or two prior lines of applicable targeted therapy that is approved for the participant's genomic alteration and platinum-based chemotherapy as the only prior line of cytotoxic therapy. Participants with AGAs may have received up to one anti-PD-1/anti-PD-L1 monoclonal antibody treatment alone or in combination with chemotherapy.

A total of approximately 40 eligible participants in China will be enrolled in this cohort, including approximately 6 participants with AGAs.

Cohort 2: The target population of Cohort 2 is adult Chinese participants with inoperable locally advanced or metastatic TNBC who have received at least 2 prior chemotherapy regimens for advanced breast cancer, counting the (neo)adjuvant therapy as a prior chemotherapy regimen if progression occurred within 12 months after completion of the therapy (DFI ≤ 12 months).

A total of approximately 78 eligible participants in China will be enrolled in this cohort. Cohort 2 will enroll at most around 20% (approximately N=15) of enrolled participants with a DFI ≤ 12 months.

Enrolled participants will be treated with Dato-DXd at 6.0 mg/kg via an IV infusion on Day 1,every 3 weeks.

The primary objective of the study is to estimate the effectiveness of Dato-DXd by assessment of confirmed ORR by independent central review.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
  • Triple Negative Breast Cancer

Keywords

  • Non-small-cell Lung Cancer
  • Triple-negative Breast Cancer
  • Dato-DXd
  • DS-1062a
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Capable of giving signed .
  • Participant must be ≥ 18 years at the time of screening.
  • performance status of 0 or 1.
  • At least one lesion not previously irradiated that qualifies as a 1.1 target lesion at baseline and can be accurately measured at baseline and is suitable for accurate repeated measurements.

Additional Inclusion Criteria for Cohort 1 (NSCLC):

- or cytologically documented Stage IIIB or IIIC NSCLC disease not amenable for surgical resection or definitive chemoradiation or Stage IV NSCLC disease at the beginning of study intervention.

For the subset of participants without AGAs:

  • Documented negative test results for EGFR and ALK genomic alterations. If test results for EGFR and ALK are not available, participants are required to undergo testing performed locally for these genomic alterations.
  • Participants must meet one of the required prior therapy requirements for advanced or NSCLC.

For the subset of participants with AGAs:

- Documented positive test results for one or more actionable genomic alteration: EGFR, ALK, ROS1, METex14 skipping, RET or other AGAs with approved therapies

- Received one or two prior lines of applicable targeted therapy for the participant's genomic alteration at the time of screening.

Additional Inclusion Criteria for Cohort 2 (TNBC)

  • Pathologically documented oestrogen and progesterone receptor-negative and -negative expression.
  • Inoperable locally advanced or metastatic breast cancer.
  • Received at least 2 prior chemotherapy regimens for locally advanced or metastatic breast cancer and previously treated with a taxane in any setting.

Key Exclusion Criteria:

  • Has or metastasis
  • Has corneal disease
  • Has known active hepatitis or uncontrolled or C infection
  • Has a history of non-infectious ILD/pneumonitis that required , has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Prior exposure to specific therapies without an adequate treatment prior to enrolment.

Additional Exclusion Criteria for Cohort 1 (NSCLC):

- Has mixed SCLC and NSCLC histology.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Dato-DXd Arm

    This single-arm study consists of multiple cohorts, divided by indication.

    Drug: Datopotamab Deruxtecan (Dato-DXd)

Interventions

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)

    Confirmed ORR is defined as the proportion of participants in each cohort who have a confirmed CR or confirmed PR, as assessed by ICR per RECIST 1.1.

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

Secondary outcomes

  1. Confirmed Objective Response Rate(ORR) Assessed by Investigator

    Confirmed ORR is defined as the proportion of participants in each cohort who have a confirmed CR or confirmed PR, as determined by investigator assessment per RECIST 1.1.

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  2. Duration of Response (DoR), Assessed by Investigator

    Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by investgator, or death due to any cause.

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  3. Disease Control Rate (DCR), Assessed by ICR

    Disease control rate is defined as the percentage of participants who have a confirmed CR or PR or who have SD per RECIST 1.1, as assessed by ICR

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  4. Best Overall Response (BoR) , Assessed by ICR

    Best overall response is defined as participant's best confirmed response during their participation in the study, but prior to starting any subsequent anticancer therapy, up until RECIST 1.1-defined PD or the last evaluable assessment in the absence of RECIST 1.1-defined progression.

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  5. Time To Response (TTR) , Assessed by ICR

    Time to response is defined as the time from the date of the first dose of study intervention until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  6. Progression-Free Survival (PFS) , Assessed by ICR

    Progression-free survival is defined as time from the date of the first dose of study intervention until progression per RECIST 1.1, as assessed by ICR, or death due to any cause.

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  7. Overall Survival (OS)

    Overall survival is defined as the time from the date of the first dose of study intervention to the date of death due to any cause.

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  8. Progression-Free Survival (PFS) , Assessed by Investigator

    Progression-free survival is defined as time from the date of the first dose of study intervention until progression per RECIST 1.1, as assessed by investigator, or death due to any cause.

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  9. Disease Control Rate (DCR), Assessed by Investigator

    Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by investigator, or death due to any cause.

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  10. Best Overall Response (BoR) , Assessed by Investigator

    Best overall response is defined as participant's best confirmed response during their participation in the study, but prior to starting any subsequent anticancer therapy, up until RECIST 1.1-defined PD or the last evaluable assessment in the absence of RECIST 1.1-defined progression.

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  11. Time To Response (TTR) , Assessed by Investigator

    Time to response is defined as the time from the date of the first dose of study intervention until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1.

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  12. Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ Total Anti-TROP2 Antibody

    PK parameters of Total Anti-TROP2 Antibody\_Area under the curve

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  13. Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Total Anti-TROP2 Antibody

    PK parameters of Total Anti-TROP2 Antibody\_Maximum observed concentration

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  14. Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _Dato-DXd

    PK parameters of Dato-DXd\_Area under the curve

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  15. Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Dato-DXd

    PK parameters of Dato-DXd\_Maximum observed concentration

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  16. Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ MAAA-1181a

    PK parameters of MAAA-1181a\_Area under the curve

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  17. Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ MAAA-1181a

    PK parameters of MAAA-1181a\_Maximum observed concentration

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  18. Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Total Anti-TROP2 Antibody

    PK parameters of Total Anti-TROP2 Antibody\_Time to maximum plasma concentration

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  19. Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Dato-DXd

    Time to maximum plasma concentration

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  20. Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _ MAAA-1181a

    PK parameters of MAAA-1181a\_Time to maximum plasma concentration

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  21. Immunogenicity of Dato-DXd

    The prevalence of ADA (positive at any visit)

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

  22. Duration of Response (DoR), Assessed by ICR

    Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by ICR, or death due to any cause.

    Time frame: TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

07

Results

Posted Jun 13, 2025

Participant flow

This Phase 1/2, open-label, multiple-cohort, single-arm study was conducted in participants with Advanced Non-Small-Cell Lung Cancer (NSCLC) and Triple-Negative Breast Cancer(TNBC) in China. For TNBC cohort, first participant was screened on 11Jul2022, last participant was screened on 27Apr2023. For NSCLC cohort, first participant was screened on 29Aug2022, last participant was screened on 21Mar2023.

Participant flow — Overall Study
MilestoneDato-DXd_NSCLCDato-DXd_TNBC
Started4079
Completed1329
Not completed2750
Withdrew: Death2743
Withdrew: Lost to follow-up07

Outcome measures

PrimaryConfirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)

Confirmed ORR is defined as the proportion of participants in each cohort who have a confirmed CR or confirmed PR, as assessed by ICR per RECIST 1.1.

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Number · Percentage of participants
Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)
Percentage of participantsTNBC CohortNSCLC Cohort
Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)33.8 (23.4 to 45.4)45.0 (29.3 to 61.5)
SecondaryConfirmed Objective Response Rate(ORR) Assessed by Investigator

Confirmed ORR is defined as the proportion of participants in each cohort who have a confirmed CR or confirmed PR, as determined by investigator assessment per RECIST 1.1.

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Number · Percentage of participants
Confirmed Objective Response Rate(ORR) Assessed by Investigator
Percentage of participantsTNBC CohortNSCLC Cohort
Confirmed Objective Response Rate(ORR) Assessed by Investigator31.2 (21.1 to 42.7)32.5 (18.6 to 49.1)
SecondaryDuration of Response (DoR), Assessed by Investigator

Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by investgator, or death due to any cause.

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Median · months
Duration of Response (DoR), Assessed by Investigator
monthsTNBC CohortNSCLC Cohort
Duration of Response (DoR), Assessed by Investigator5.8 (4.01 to 8.4)8.1 (4.2 to 11.2)
SecondaryDisease Control Rate (DCR), Assessed by ICR

Disease control rate is defined as the percentage of participants who have a confirmed CR or PR or who have SD per RECIST 1.1, as assessed by ICR

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Number · Percentage
Disease Control Rate (DCR), Assessed by ICR
PercentageTNBC CohortNSCLC Cohort
Disease Control Rate (DCR), Assessed by ICR72.7 (61.4 to 82.3)85 (70.2 to 94.3)
SecondaryBest Overall Response (BoR) , Assessed by ICR

Best overall response is defined as participant's best confirmed response during their participation in the study, but prior to starting any subsequent anticancer therapy, up until RECIST 1.1-defined PD or the last evaluable assessment in the absence of RECIST 1.1-defined progression.

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Number · Percentage
Best Overall Response (BoR) , Assessed by ICR
PercentageTNBC CohortNSCLC Cohort
Confirmed Partial Response33.845.0
Confirmed Complete Response00
SecondaryTime To Response (TTR) , Assessed by ICR

Time to response is defined as the time from the date of the first dose of study intervention until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Median · Month
Time To Response (TTR) , Assessed by ICR
MonthTNBC CohortNSCLC Cohort
Time To Response (TTR) , Assessed by ICR1.5 (1.3 to 2.8)1.4 (1.3 to 2.7)
SecondaryProgression-Free Survival (PFS) , Assessed by ICR

Progression-free survival is defined as time from the date of the first dose of study intervention until progression per RECIST 1.1, as assessed by ICR, or death due to any cause.

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Median · Month
Progression-Free Survival (PFS) , Assessed by ICR
MonthTNBC CohortNSCLC Cohort
Progression-Free Survival (PFS) , Assessed by ICR5.3 (4.2 to 6.9)8.0 (5.7 to 10.8)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from the date of the first dose of study intervention to the date of death due to any cause.

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Median · Month
Overall Survival (OS)
MonthTNBC CohortNSCLC Cohort
Overall Survival (OS)13.5 (10.7 to NA)16.7 (13.8 to 20.4)
SecondaryProgression-Free Survival (PFS) , Assessed by Investigator

Progression-free survival is defined as time from the date of the first dose of study intervention until progression per RECIST 1.1, as assessed by investigator, or death due to any cause.

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Median · Month
Progression-Free Survival (PFS) , Assessed by Investigator
MonthTNBC CohortNSCLC Cohort
Progression-Free Survival (PFS) , Assessed by Investigator4.3 (4.0 to 5.6)7.0 (5.5 to 9.5)
SecondaryDisease Control Rate (DCR), Assessed by Investigator

Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by investigator, or death due to any cause.

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Number · Percentage
Disease Control Rate (DCR), Assessed by Investigator
PercentageTNBC CohortNSCLC Cohort
Disease Control Rate (DCR), Assessed by Investigator76.6 (65.6 to 85.5)85.0 (70.2 to 94.3)
SecondaryBest Overall Response (BoR) , Assessed by Investigator

Best overall response is defined as participant's best confirmed response during their participation in the study, but prior to starting any subsequent anticancer therapy, up until RECIST 1.1-defined PD or the last evaluable assessment in the absence of RECIST 1.1-defined progression.

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Number · Percentage
Best Overall Response (BoR) , Assessed by Investigator
PercentageTNBC CohortNSCLC Cohort
Confirmed complete response00
Confirmed partial response31.232.5
SecondaryTime To Response (TTR) , Assessed by Investigator

Time to response is defined as the time from the date of the first dose of study intervention until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1.

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Median · Month
Time To Response (TTR) , Assessed by Investigator
MonthTNBC CohortNSCLC Cohort
Time To Response (TTR) , Assessed by Investigator1.4 (1.4 to 1.6)1.4 (1.3 to 1.4)
SecondaryPharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ Total Anti-TROP2 Antibody

PK parameters of Total Anti-TROP2 Antibody\_Area under the curve

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Geometric mean · day*ug/mL
Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ Total Anti-TROP2 Antibody
day*ug/mLTNBC CohortNSCLC Cohort
Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ Total Anti-TROP2 Antibody713.9 ± 25.45569.3 ± 24.47
SecondaryPharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Total Anti-TROP2 Antibody

PK parameters of Total Anti-TROP2 Antibody\_Maximum observed concentration

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Geometric mean · ug/mL
Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Total Anti-TROP2 Antibody
ug/mLTNBC CohortNSCLC Cohort
Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Total Anti-TROP2 Antibody151.1 ± 11.62115.5 ± 22.99
SecondaryPharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _Dato-DXd

PK parameters of Dato-DXd\_Area under the curve

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Geometric mean · day*ug/mL
Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _Dato-DXd
day*ug/mLTNBC CohortNSCLC Cohort
Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _Dato-DXd668.3 ± 21.11504.5 ± 22.38
SecondaryPharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Dato-DXd

PK parameters of Dato-DXd\_Maximum observed concentration

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Geometric mean · ug/mL
Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Dato-DXd
ug/mLTNBC CohortNSCLC Cohort
Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ Dato-DXd150.9 ± 12.73108.7 ± 11.30
SecondaryPharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ MAAA-1181a

PK parameters of MAAA-1181a\_Area under the curve

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Geometric mean · day*ng/mL
Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ MAAA-1181a
day*ng/mLTNBC CohortNSCLC Cohort
Pharmacokinetic Parameter: Area Under the Plasma Concentration- Time Curve (AUC) _ MAAA-1181a17.60 ± 24.6417.66 ± 33.09
SecondaryPharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ MAAA-1181a

PK parameters of MAAA-1181a\_Maximum observed concentration

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ MAAA-1181a
ng/mLTNBC CohortNSCLC Cohort
Pharmacokinetic Parameter: Maximum Plasma Concentration (Cmax) _ MAAA-1181a2.976 ± 25.842.231 ± 27.51
SecondaryPharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Total Anti-TROP2 Antibody

PK parameters of Total Anti-TROP2 Antibody\_Time to maximum plasma concentration

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Median · Hour
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Total Anti-TROP2 Antibody
HourTNBC CohortNSCLC Cohort
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Total Anti-TROP2 Antibody4.87 (1.55 to 7.17)1.58 (1.38 to 6.83)
SecondaryPharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Dato-DXd

Time to maximum plasma concentration

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Median · h
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Dato-DXd
hTNBC CohortNSCLC Cohort
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _Dato-DXd4.95 (1.83 to 7.17)1.63 (1.38 to 5.22)
SecondaryPharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _ MAAA-1181a

PK parameters of MAAA-1181a\_Time to maximum plasma concentration

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Median · Hour
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _ MAAA-1181a
HourTNBC CohortNSCLC Cohort
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) _ MAAA-1181a6.09 (4.87 to 24.22)22.52 (6.85 to 25.07)
SecondaryImmunogenicity of Dato-DXd

The prevalence of ADA (positive at any visit)

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Number · percentage
Immunogenicity of Dato-DXd
percentageTNBC CohortNSCLC Cohort
Immunogenicity of Dato-DXd33.336.8
SecondaryDuration of Response (DoR), Assessed by ICR

Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by ICR, or death due to any cause.

Time frame:
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Reported as:
Median · Month
Duration of Response (DoR), Assessed by ICR
MonthTNBC CohortNSCLC Cohort
Duration of Response (DoR), Assessed by ICR6.7 (4.53 to 12.6)8.3 (5.9 to 9.4)

Adverse events

Collected over Adverse Events had a median follow-up of 6.13 months for NSCLC cohort and 4.99 months for TNBC cohort. All-Cause Mortality was assessed from enrollment to 13 months post last subject dose with a median of 12 months follow up for the TNBC cohort, and from enrollment to 20 months post last subject dose with a median of 16.7 months follow up for the NSCLC cohort.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dato-DXd_NSCLC27/40 (67.5%)12/40 (30%)38/40 (95%)
Dato-DXd_TNBC43/79 (54.4%)13/79 (16.5%)77/79 (97.5%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventDato-DXd_NSCLCDato-DXd_TNBC
PneumoniaInfections and infestations2/406/79
Decreased appetiteMetabolism and nutrition disorders3/400/79
Covid-19Infections and infestations0/402/79
NauseaGastrointestinal disorders1/400/79
VomitingGastrointestinal disorders1/400/79
Gastrointestinal infectionInfections and infestations1/400/79
Pneumonia bacterialInfections and infestations1/400/79
SyncopeNervous system disorders1/400/79
HaemoptysisRespiratory, thoracic and mediastinal disorders1/400/79
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders1/401/79
Most frequent other events
Showing 10 of 65
Most frequent other events
EventDato-DXd_NSCLCDato-DXd_TNBC
NauseaGastrointestinal disorders24/4034/79
StomatitisGastrointestinal disorders23/4038/79
AnaemiaBlood and lymphatic system disorders23/4020/79
AlopeciaSkin and subcutaneous tissue disorders16/408/79
Neutrophil count decreasedInvestigations7/4026/79
VomitingGastrointestinal disorders13/4023/79
White blood cell count decreasedInvestigations3/4025/79
Weight decreasedInvestigations12/4010/79
ConstipationGastrointestinal disorders11/4019/79
Decreased appetiteMetabolism and nutrition disorders11/4015/79

Baseline characteristics

FAS: Enrolled participants who have received at least one dose of treatment.

Age, Continuous
Age, Continuous(Year)Dato-DXd_NSCLCDato-DXd_TNBCTotal
Mean59.4 ± 9.750.3 ± 10.254.85 ± 9.95
Sex: Female, Male
Sex: Female, Male(Participants)Dato-DXd_NSCLCDato-DXd_TNBCTotal
Female117990
Male29029
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dato-DXd_NSCLCDato-DXd_TNBCTotal
American Indian or Alaska Native000
Asian4079119
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Dato-DXd_NSCLCDato-DXd_TNBCTotal
China4079119
08

Study locations

21 sites
  • Research Site
    Beijing, 100039, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changchun, 130012, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Dalian, 116023, China
  • Research Site
    Fuzhou, 350001, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Jinan, 250030, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanchang, 330009, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Nov 2023, 15 months.

Results were first posted in Jun 2025, 1 year 7 months after primary completion.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 15 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2022
First posted
Jul 15, 2022
StartActual
Jul 11, 2022
Primary completionActual
Nov 7, 2023
CompletionEst.
Jun 30, 2027
Results first posted
Jun 13, 2025
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05460273
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jul 15, 2022
Start date
Jul 11, 2022
Primary completion
Nov 7, 2023
Completion
Jun 30, 2027 (estimated)
Results posted
Jun 13, 2025
Last update
Aug 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion